Healthcare resource utilization for recurrent Clostridium difficile infection in a large university hospital in Houston, Texas

PLoS One. 2014 Jul 24;9(7):e102848. doi: 10.1371/journal.pone.0102848. eCollection 2014.

Abstract

Background: There are limited data examining healthcare resource utilization in patients with recurrent Clostridium difficile infection (CDI).

Methods: Patients with CDI at a tertiary-care hospital in Houston, TX, were prospectively enrolled into an observational cohort study. Recurrence was assessed via follow-up phone calls. Patients with one or more recurrence were included in this study. The location at which healthcare was obtained by patients with recurrent CDI was identified along with hospital length of stay. CDI-attributable readmissions, defined as a positive toxin test within 48 hours of admission and a primary CDI diagnosis, were also assessed.

Results: 372 primary cases of CDI were identified of whom 64 (17.2%) experienced at least one CDI recurrence. Twelve of 64 patients experienced 18 further episodes of CDI recurrence. Of these 64 patients, 33 (50.8%) patients with recurrent CDI were readmitted of which 6 (18.2%) required ICU care, 29 (45.3%) had outpatient care only, and 2 (3.1%) had an ED visit. Nineteen (55.9%) readmissions were defined as CDI-attributable. For patients with CDI-attributable readmission, the average length of stay was 6 ± 6 days.

Conclusion: Recurrent CDI leads to significant healthcare resource utilization. Methods of reducing the burden of recurrent CDI should be further studied.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Clostridioides difficile / physiology*
  • Clostridium Infections / drug therapy
  • Clostridium Infections / economics*
  • Clostridium Infections / microbiology
  • Cross Infection / drug therapy
  • Cross Infection / economics*
  • Cross Infection / microbiology
  • Female
  • Hospitals, University / economics*
  • Hospitals, University / statistics & numerical data
  • Humans
  • Length of Stay / economics*
  • Male
  • Metronidazole / therapeutic use
  • Middle Aged
  • Prospective Studies
  • Recurrence
  • Texas
  • Vancomycin / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Metronidazole
  • Vancomycin

Grants and funding

YX is an employee of Merck. He was an epidemiologic consultant on this manuscript and also provided advice on the final draft of the manuscript. The funders had no role in study design, data collection and analysis, or decision to publish.